Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources
←Back to briefings
Rua Bioscience (RUA) / HY23

Reported $0.7m profit masks unchanged $3.7m cash burn against $1.7m balance

Non-cash items drove the swing to NPAT while operating cash outflow held near prior levels and the cash balance fell 24.5%.

Healthcare / Medicinal cannabis

RUA revenue trajectory

Revenue context before the current result.

↗
Loading chart...
HY23 was $0.25m, versus $360m in HY22.

RUA operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
HY23 was -$3.7m, versus -$3.7m in HY22.

RUA NPAT trajectory

Statutory profit after tax across covered periods.

↗
Loading chart...
HY23 was $0.7m, versus -$2.5m in HY22.

RUA pre-lease FCF

Operating cash flow less capex before leases.

↗
Loading chart...
HY23 was -$3.7m, versus -$4m in HY22.

Market context

Valuation

A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.

Prices as at close, 8 June 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$10.2m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

Not available

i

Not available for this company right now.

EPS

Not available

i

Not available for this company right now.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

Not available

i

Not available for this company right now.

P/FCF

Not available

i

Not available for this company right now.

P/B

1.74x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
28 February 2023
Published
23 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources

Key metrics

Numbers worth scanning first

HY23 vs HY22

Revenue

$0.25m

-29.4% ↓ vs $0.36m

Net profit after tax

$0.7m

+128.0% ↑ vs −$2.5m

Net cash inflow from operating activities

−$3.7m

+1.7% ↑ vs −$3.7m

Operating profit

$0.63m

+116.2% ↑ vs −$3.9m

Profit before tax

$0.7m

+120.0% ↑ vs −$3.5m

Cash and cash equivalents

$1.7m

-24.5% ↓ vs $2.3m

Total assets

$29.1m

+3.8% ↑ vs $28m

What changed

Cash burn from operations was essentially unchanged at -$3.7m versus -$3.7m in HY22, but the cash balance fell 24.5% to $1.708m from $2.263m

With half-year operating outflows at roughly twice the closing cash position, runway is the dominant issue in this release.

Against that backdrop, reported earnings swung sharply: NPAT moved to +$0.719m from -$2.465m (+129.2%) and PBT moved to +$0.719m from -$3.478m (+120.7%). Management's own commentary references "excluding fair [value]" gains, indicating non-cash items drove the swing. Revenue fell 29.4% to $0.254m on a sub-million base. The company also ceased manufacturing during the period and signalled an imminent German launch.

What matters

Runway is tight

Cash of $1.708m against half-year operating cash outflow of $3.664m implies less than six months of cover at the current burn rate before any further capital raise, working-capital release, or revenue ramp. Capex dropped to -$0.047m from -$0.311m (-84.9%), consistent with the decision to exit manufacturing, but it does not close the operating gap.

Reported profit does not reflect operating economics. FCF-to-NPAT of -516.4% versus +163.9% in HY22 confirms that the profit print is non-cash in nature. PBT growth of 120.7% is the cleaner accounting read, but even that overstates the underlying trajectory because operating cash outflows of $3.7m are largely unchanged year-on-year. The "fair value" reference in management's commentary is the disclosed driver investors need to size.

Strategy has pivoted before commercial revenue has arrived. Revenue fell 29.4% on a base that was already small, and the company is now reliant on third-party manufacturing plus European market entry (Germany launch-ready, Poland positioning) to generate the revenue scale needed to narrow the cash burn. This matters because the equity story has shifted from domestic build-out to export execution while operating losses continue.

Expectations

No forward targets, forward-work value, or quantified revenue guidance are supplied for HY23

Management describes German launch as "imminent" and first revenues as "tantalisingly close," but neither timing nor sizing is disclosed. Prior-year shape data is not reliable enough to anchor a second-half expectation, so the release on its own supports only a qualitative read: H2 needs to deliver visible export revenue and a step-down in burn, otherwise capital adequacy becomes the binding constraint.

The gap between the qualitative tone of the commentary ("results as expected," "well-positioned") and the cash-balance trajectory is the central tension going into the second half.

Quality of result

The reported profit is low-quality on the available evidence

Operating cash outflow of -$3.664m is essentially flat to -$3.728m a year earlier, while NPAT moved by +$3.184m. That divergence is reconciled by management's reference to fair-value gains rather than by improved trading. The headline tax-rate optics (0.0% current versus 29.1% prior) are also a function of the swing to profit on a non-cash item rather than an underlying tax outcome, so they should not be read as a recurring earnings lift.

Operating working-capital movement is immaterial at the group level, so the cash position is being depleted by operating losses rather than by inventory or receivables build. Inventories rose 64.3% to $0.138m but remain small in absolute terms. Total equity of $26.7m is roughly flat year-on-year, so the balance sheet is not yet flagging an impairment cycle, but ROE of 2.7% on a non-cash-driven profit overstates the economic return on that equity base.

Unresolved

Open questions

What specific fair-value or non-cash adjustment drove the swing from a $3.5m PBT loss to a $0.7m PBT profit, and how should investors treat it for run-rate purposes?
How long does management believe the $1.708m closing cash balance funds operations, and what is the funding plan if German and Polish revenues do not ramp in H2?
What revenue contribution is realistic from the German launch within the FY23 period, and what is the gross-margin shape under the third-party manufacturing model?
Why did revenue decline 29.4% in a period management characterises as in line with expectations, and what is the bridge from $0.254m HY23 revenue to a sustainable run rate?
How will the cessation of in-house manufacturing affect domestic supply, unit economics, and any committed customer relationships?

This briefing cannot assess the size or recurrence of the fair-value gain, the exact runway, or the credibility of the European launch timeline because the release does not quantify those items.

Chat

Ask about RUA HY23

Ask follow-up questions about Rua Bioscience's HY23 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about RUA HY23

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Rua Bioscience's HY23 result.

What specific fair-value or non-cash adjustment drove the swing from a $3.5m PBT loss to a $0.7m PBT profit, and how should investors treat it for run-rate purposes?Why does "Runway is tight" matter?How strong was the cash and earnings quality in HY23?What should I watch next for RUA after HY23?

Checking account...

Data appendix

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

company filing

HY23 / results announcement↗

Interim Financial Statements 31 December 2022

HY23 / financial report↗

Interim Financial Statements Market Announcement

HY23 / results release↗

Prior comparable period

Results Announcement

HY22 / results announcement↗

Rua Bioscience Interim Financial Statements Market Announcement

HY22 / results release↗

Rua Bioscience Limited Interim Financial Statements - 31 December 2021

HY22 / financial report↗

Full-year context

company filing

FY22 / results announcement↗

company filing

FY22 / results release↗

Rua Bioscience Ltd - FY22 Financial Statements

FY22 / financial report↗

Release context

Rua Accelerates Export Strategy, Ceases Manufacturing

HY23 / commentary↗

Announcement - ASM Slides and Commentary Available

HY23 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 8.5pp, with a distortion flag in the result.

→

Revenue growth context

Revenue growth was -29.4% for this reporting period.

→

ROE and capital efficiency

ROE was 2.7%, +12.0pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when RUA publishes next

Get the next Rua Bioscience briefing and related NZX reporting-season updates by email.